Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 9/20 | 0.64 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851696 | 0.88 | GPR52 (0.77) | GPR52DGAT2S1PR4S1PR5LOX | |
| SCHEMBL3222989 | 0.88 | GPR52 (0.76) | GPR52S1PR4S1PR5MRGPRX4 | |
| SCHEMBL3209604 | 0.87 | GPR52 (0.65) | GPR52S1PR4S1PR5MRGPRX4LOX | |
| SCHEMBL1855951 | 0.86 | GPR52 (0.70) | GPR52S1PR4S1PR5MRGPRX4LOX | |
| SCHEMBL1854620 | 0.84 | GPR52 (0.62) | GPR52S1PR4S1PR5MRGPRX4HDAC4 | |
| SCHEMBL3219557 | 0.82 | GPR52 (0.61) | GPR52MRGPRX4LOXLOXL2 | |
| SCHEMBL1856153 | 0.82 | GPR52 (0.77) | GPR52S1PR4S1PR5MRGPRX4 | |
| SCHEMBL1848618 | 0.81 | GPR52 (0.77) | GPR52S1PR4S1PR5MRGPRX4 | |
| SCHEMBL3216142 | 0.80 | GPR52 (0.65) | GPR52S1PR4S1PR5MRGPRX4HDAC4 | |
| SCHEMBL3197821 | 0.79 | GPR52 (0.62) | GPR52S1PR4S1PR5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885DGAT2 774/4885S1PR4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.